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Editorial on the Research Topic
Leeway to Operate With Plant Genetic Resources
Different legal frameworks are applicable to the use of genetic resources (GR). These can broadly
be categorized into (1) access and benefit-sharing (ABS), (2) biosafety aspects related to the
technologies for improving the geneticmaterial, and (3) intellectual property (IP) systems including
plant variety rights (PVR) and patents specific to the plant innovation sector. With scientific
and technical progress in research and breeding, as well as expanding internationalization, legal
frameworks have become increasingly complex in the past few decades. In this context, the Research
Topic “Leeway to operate with plant genetic resources” addresses the latest andmost pertinent legal
issues related to the use of GR in plant research and breeding. The contributions are summarized
here and put into the larger societal and legal context that modern-day plant geneticists are facing.
ACCESS AND BENEFIT-SHARING
ABS is a framework that aims to distribute fairly the benefits arising from the utilization of GR
between users and providers. The basic principles are drawn in the Convention on Biological
Diversity (CBD) and its supplementary protocol, the Nagoya Protocol (https://cbd.int/abs/). The
access to GR also considers the related traditional knowledge and is based on prior informed
consent and mutually agreed terms.
There is a wide disparity in how the Nagoya Protocol is implemented in different countries,
which is challenging for users. Sirakaya et al. reviews the ABS framework across 20 provider
countries, identifying common regulatory elements and follows up with stakeholder interviews.
These show that opinions on the benefits of various ABS regulatory mechanisms differ between
provider countries and industrial users, though there are some common grounds. One significant
detail is that most users oppose the inclusion of digital sequence information (DSI) within the
subject matter, contrary to most provider countries. We note that FAO acknowledges that DSI
increases the understanding ofmolecular biology and evolution as well as taxonomy and identifying
species, thus facilitating GR conservation and use. Aubry et al. elaborates further on the ongoing
debate about the sharing and mining of freely accessible sequencing data. In his view, DSI of
plant genetic resources for food and agriculture (PGRFA) should be under an “efficient, resilient,
decentralized” and reasonable governance model that ensures its fair use.
Brink and van Hintum address the perspective of collection holders, showing the challenges
faced by gene banks for acquiring and sharing GR while complying with the various international
and national regulations. They argue that gene banks must set up appropriate protocols for
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documenting every accession’s origin and the condition for its
use and further distribution, while countering complexity to
avoid a decrease in access to PGRFA. Overall, it is important to
ensure fair and equitable ABS negotiations between providers
and users. Deplazes-Zemp et al. brings an ethical perspective,
arguing that there are five types of justice related to this
subject: distributive, commentative, recognitive, reparative, and
procedural. According to the author, it is important that both
users and providers are aware of these justice types and the way
the use of GR poses particular challenges.
BIOSAFETY
The products of gene technologies, such as genetically modified
organisms (GMOs) are subject to a specific biosafety legislation,
in most jurisdictions. building on principles established by the
Cartagena Protocol to the CBD (https://bch.cbd.int/protocol/).
The legal status of the products of new breeding techniques
(NBTs) has been subject to many discussions, as the resulting
products may or may not be encompassed by the GMO
definition, depending on the jurisdiction.
A landmark judgment from the Court of Justice of the
European Union (CJEU) in July 2018 (case C-528/16) means
that the products of site-directed mutagenesis will be subject
to the same legal provisions as genetically modified organisms
(GMOs). There are however discussions on the applicability of
the CJEU judgment to the variety of NBT products. Vives-Vallés
and Collonnier provide a legal interpretation of the judgment,
relating it to relevant scientific papers published in the aftermath.
Their article concludes that certain products of NBTs may
be exempted from the scope of Directive 2001/18/EC, despite
the CJEU judgment being commonly interpreted otherwise,
and sketches a limited legislative proposal to achieve certainty
and suggesting which NBT products could be exempted and
under what circumstances. Holme et al. argues that the CJEU
assumption that targeted mutagenesis “makes it possible to
produce GM varieties at a rate and in quantities unlike those
resulting from random mutagenesis,” is incorrect. Technical
developments including TILLING has led to a convergence
between the two types of mutagenesis in terms of output, with
the main differences being the precision of mutation site and the
number of off-target mutations.
Turning to the economics of regulating NBT products,
Wesseler et al. compares theoretical advantages and
disadvantages with different regulatory approaches. A survey
among Dutch plant breeding companies show that these are
optimistic the prospect that a more relaxed legislation will be
implemented in the EU, despite having experienced a negative
impact on competitiveness and on investments due to the CJEU
judgment on mutagenesis. Jin et al. present an example of
costs in delaying technology adoption. By assessing the impact
caused by postponed authorization for the use of Bt rice in
China, the authors model the costs by filling an information
gap regarding foregone benefits of lower pesticide use and the
spill-over effect by delaying technology adoption. They conclude
that delaying Bt rice introduction has come at a substantial
economic cost (both direct as well as in terms of human health
and environmental costs).
The Green Revolution based on crop genetics along with
advanced agronomy led to miraculous harvests in Asia and
Latin America, but largely bypassed sub-Saharan Africa. The
ongoing gene revolution should therefore bring benefits to this
region. Komen et al. show how the authorization of transgenic
crops release is managed, drawing examples from five African
countries. They highlight challenges and lessons learnt and
propose policy recommendations facilitating the adoption of
emerging biotechnology for plant breeding in Africa. It has
however been recognized elsewhere in the literature that the
global influence of EU policies should be considered. The
overall process for risk assessment and risk management of
GMOs in the EU has been criticized as being unnecessary
politicized and, though the part with the science-based system
for risk assessment is overall sound, certain improvements are
envisaged by Chatzopoulou et al.. The authors compare the
procedure in the European Food Safety Authority (EFSA) with
that of the European Medicines Agency (EMA), and suggest
that a more balanced geographical distribution of experts in
the EFSA GMO panel may minimize overall politicization of
decision-making.
INTELLECTUAL PROPERTY
Current technical developments are posing challenges to the
IP/PVR systems in plant breeding. Definitions need to be re-
established and the impact of the evolution of systems for
patents and for plant breeders’ rights need to be analyzed in
terms of market structure and competition. One example is the
concept of Essentially Derived Variety (EDV), for which UPOV is
currently revisiting their explanatory note. Krieger et al. explore
the concept and assess whether the use of NBTs invariably leads to
an EDV. The authors deliver a legal interpretation of two related
notions, namely, the “breeder’s exemption” and EDV, considering
the wording of the provisions, the historical background and the
evolution, including also assertions from case law from several
UPOVmembers. Several elements are discussed, concluding that
the EDV concept should encompass cultivars obtained through
the application of NBT only, when no further significant breeding
steps have been taken.
In terms of market structure and innovation, Wozniak et al.
analyse the current situation and prospects of rapeseed in the
EU taking Poland and Germany as benchmarks. The study
considers several IP as well as agronomic factors and analyses
their evolution overtime, describing patterns regarding the
opportunities of rapeseed. Though an analysis of IP shows an
innovation potential, the authors are concerned that the CJEU
judgment on mutagenesis may have a negative impact on the
expansion of rapeseed cultivation.
Following concerns about the increasing impact of patenting
and of concentration in the seed sector, an Open Source Seed
(OSS) model has been proposed in recent years. Louwaars et al.
investigates this model and its impact on the breeder’s exemption
specifically and on the open innovation character of the PVR
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system in general. Focusing on two examples from Germany
and USA, the author suggests that OSS models add additional
pressure on the breeder’s exemption, which may already be
restrained by patents and biodiversity schemes, thus concluding
that the breeder’s exemption is an appropriate solution to ensure
the access to genetic material.
Altogether, these articles illustrate the complexity of legal
frameworks that plant researchers and breeders need to be
aware of and comply with. Scientific and technological progress
is enhancing our capacity to work with GR and causes
restructuring of markets and competition and re-definitions of
established concepts. We hope this Research Topic will provide a
valuable resource for all stakeholders, including scientists, legal
researchers, and practitioners that wish to stay up to date in
this field.
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